Stevanato Group

Stevanato Group

STVN
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Market Cap: $944.5MFounded: 1949Employees: 4000-6000HQ: Piombino Dese, Italy

Overview

Stevanato Group is a mission-critical enabler for the global pharmaceutical industry, providing high-quality integrated solutions for drug containment, delivery, and diagnostics. Its strategy leverages deep expertise in glass science, engineering, and contract manufacturing to support the development and commercialization of complex therapeutics, particularly biologics and high-concentration formulations. The company has achieved a leading global position through strategic international expansion, continuous innovation, and a strong focus on quality and customer partnership. Its public listing and consistent revenue growth reflect its scale and integral role in the healthcare supply chain.

Drug Delivery

Technology Platform

Integrated platform combining 1) Drug Containment (pharmaceutical glass science), 2) Drug Delivery Systems (device engineering & manufacturing), and 3) Engineering & Diagnostic Solutions (machinery, analytics, and services).

Funding History

1
Series AUndisclosed

Opportunities

The company is poised to capitalize on the rapid growth of biologics and biosimilars, the strong trend toward self-administration and home healthcare, and the pharmaceutical industry's strategic shift toward building resilient, regionalized supply chains.
Its integrated solutions model is uniquely suited to address the increasing technical complexity of modern drugs.

Risk Factors

Key risks include customer concentration among large pharma companies, volatility in energy and raw material costs critical for glass production, potential technological disruption from alternative materials to glass, and execution risks associated with major capacity expansions like the new U.S.
plant.

Competitive Landscape

Stevanato faces competition in segments from giants like Schott AG and Corning in glass containment, and from CDMOs like West Pharmaceutical Services and Gerresheimer in drug delivery devices. Its primary competitive advantage is its unique, integrated end-to-end model combining deep glass science with device engineering and manufacturing.